Side-stepping the guardian of the genome: current cancer therapeutics targeting mutant p53
Cancer therapies have attempted to target the transcription factor p53, a gene also described as the “guardian of the genome,” for decades. However, the approach has faced numerous barriers to clinical efficacy due to several factors: mutations in p53 occur in almost half of all human cancers, mutat...
Saved in:
Main Authors: | Iulianna C. Taritsa, Eric T. Fossel |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1529483/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Editorial: Tumor microenvironment complexity and its therapeutic implications
by: Denner Santos dos Anjos, et al.
Published: (2025-01-01) -
TP53 Mutation Predicts Worse Survival and Earlier Local Progression in Patients with Hepatocellular Carcinoma Treated with Transarterial Embolization
by: Ken Zhao, et al.
Published: (2025-01-01) -
Opportunities and challenges of immuno-oncology: A bibliometric analysis from 2014 to 2023
by: Siqi Zhang, et al.
Published: (2025-12-01) -
RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties
by: Barnabas Nyesiga, et al.
Published: (2024-12-01) -
Therapeutic alliance in a stepped digital psychosocial intervention for breast cancer patients: findings from a multicentre randomised controlled trial
by: Aida Flix-Valle, et al.
Published: (2025-01-01)